Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - cream - excipient ingredients: sodium hydroxide; titanium dioxide; purified water; carbomer 980; propylene glycol - for the relief of the inflammatory and pruritic manifestations of resistant or severe corticosteroid responsive dermatoses. these include atopic eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus and psoriasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone dipropionate, quantity: 0.64 mg/g (equivalent: betamethasone, qty 0.5 mg/g) - ointment - excipient ingredients: white soft paraffin; propylene glycol; propylene glycol monostearate; white beeswax - for the relief of the inflammatory and pruritic manifestations of resistant or severe corticosteroid responsive dermatoses. these include atopic eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus and psoriasis. diprosone ov ointment is also indicated for the maintenance of remission in chronic psoriasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - betamethasone dipropionate 0.065% equivalent to 0.05% betamethasone;   - topical cream - 0.05 % - active: betamethasone dipropionate 0.065% equivalent to 0.05% betamethasone   excipient: carbomers propylene glycol purified water sodium hydroxide titanium dioxide

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - betamethasone dipropionate; salicylic acid - cutaneous solution - 0.05 %w/w+2 percent weight/weight - corticosteroids, potent, other combinations; betamethasone

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate cream is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. betamethasone dipropionate cream is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate cream usp (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate cream usp (augmented), 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate cream usp (augmented), 0.05% use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate cream usp (augmented), 0.05% may increase the risk of having a low birthweight infant and to use betamethasone dipropio

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.